Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Ionis Pharmaceuticals Inc (NASDAQ: IONS) was $82.7 for the day, up 2.19% from the previous closing price of $80.93. In other words, the price has increased by $2.19 from its previous closing price. On the day, 2.96 million shares were traded. IONS stock price reached its highest trading level at $82.905 during the session, while it also had its lowest trading level at $80.75.
Ratios:
Our analysis of IONS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 3.32 whereas as Long-Term Debt/Eq ratio is at 2.27.
On September 26, 2025, Goldman Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $65.
BMO Capital Markets Upgraded its Market Perform to Outperform on September 03, 2025, while the target price for the stock was maintained at $70.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 25 ’25 when Devers Shannon L. bought 42,322 shares for $80.91 per share.
KLEIN JOSEPH III bought 12,000 shares of IONS for $960,000 on Nov 25 ’25. On Nov 19 ’25, another insider, HERMAN JOAN E, who serves as the Director of the company, sold 44,000 shares for $72.13 each. As a result, the insider received 3,173,830 and left with 46,086 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 13395281920 and an Enterprise Value of 13211331584. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.85 while its Price-to-Book (P/B) ratio in mrq is 21.56. Its current Enterprise Value per Revenue stands at 13.663 whereas that against EBITDA is -49.518.
Stock Price History:
The Beta on a monthly basis for IONS is 0.29, which has changed by 1.3145816 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $81.20, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 16.70%, while the 200-Day Moving Average is calculated to be 79.80%.
Shares Statistics:
IONS traded an average of 2.84M shares per day over the past three months and 3805720 shares per day over the past ten days. A total of 161.14M shares are outstanding, with a floating share count of 158.84M. Insiders hold about 1.94% of the company’s shares, while institutions hold 103.67% stake in the company. Shares short for IONS as of 1763078400 were 14223973 with a Short Ratio of 5.01, compared to 1760486400 on 13699358. Therefore, it implies a Short% of Shares Outstanding of 14223973 and a Short% of Float of 11.59.
Earnings Estimates
Ionis Pharmaceuticals Inc (IONS) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.34 and low estimates of -$0.68.
Analysts are recommending an EPS of between -$1.2 and -$1.87 for the fiscal current year, implying an average EPS of -$1.61. EPS for the following year is -$2.06, with 11.0 analysts recommending between -$1.08 and -$2.98.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 15 analysts. It ranges from a high estimate of $170.59M to a low estimate of $125M. As of. The current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $227MFor the next quarter, 15 analysts are estimating revenue of $188.91M. There is a high estimate of $242M for the next quarter, whereas the lowest estimate is $145.53M.
A total of 21 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $922.7M, while the lowest revenue estimate was $865M, resulting in an average revenue estimate of $896.05M. In the same quarter a year ago, actual revenue was $705MBased on 21 analysts’ estimates, the company’s revenue will be $923.88M in the next fiscal year. The high estimate is $1.15B and the low estimate is $686.83M.
